Crocco Todd, Gullett Travis, Davis Stephen M, Flores Nicole, Sauerbeck Laura, Jauch Edward, Threlkeld Billie, Pio Brian, Ottaway Michael, Pancioli Arthur, Chenier Thomas
Department of Emergency Medicine, West Virginia University, Morgantown, WV 26506-9149, USA.
Stroke. 2003 Aug;34(8):1918-22. doi: 10.1161/01.STR.0000080943.59701.0D. Epub 2003 Jul 3.
Studies have demonstrated the importance of early stroke treatment. If a neuroprotective agent (NA) clinical trial is successful, the greatest benefit might be attained with early prehospital administration. This study determined the potential reduction in time to treatment of stroke patients when NAs were administered in the prehospital setting.
Twenty-three urban emergency medical services (EMS) agencies participated in this study. Prehospital personnel completed a stroke assessment checklist on any potential stroke victim. The checklist collected clinical inclusion/exclusion criteria for NA administration and event/decision times. Patients meeting the hypothetical clinical inclusion criteria were enrolled into this study. Time data included scene arrival/departure, emergency department (ED) arrival, and estimated time of theoretical NA administration. The reduction in time to stroke treatment was calculated as the difference between the time of ED arrival and the reported time of NA administration. The t test and simple linear regression were used to probe for differences in treatment time reduction between selected subgroups. EMS personnel's ability to obtain informed consent for theoretical NA administration was calculated.
Two hundred twenty-two patients were enrolled in this study; of these, 75 were deemed eligible for hypothetical NA administration and had complete time data. On average, EMS personnel documented the theoretical time of NA administration at 12.04+/-2.07 minutes before arrival at the ED (17.06+/-1.74 minutes when the NA was given on scene [n=43]; 6.65+/-1.14 minutes when the NA was given en route [n=32]).
Prehospital NA administration can potentially significantly reduce the time to first intervention in stroke patients.
研究已证实早期卒中治疗的重要性。如果一种神经保护剂(NA)临床试验成功,那么在院前早期给药可能会获得最大益处。本研究确定了在院前环境中给予NA时,卒中患者治疗时间可能减少的情况。
23个城市紧急医疗服务(EMS)机构参与了本研究。院前急救人员对任何疑似卒中患者完成一份卒中评估清单。该清单收集了NA给药的临床纳入/排除标准以及事件/决策时间。符合假设临床纳入标准的患者被纳入本研究。时间数据包括现场到达/离开时间、急诊科(ED)到达时间以及理论上NA给药的估计时间。卒中治疗时间的减少量计算为ED到达时间与报告的NA给药时间之差。采用t检验和简单线性回归来探究选定亚组之间治疗时间减少的差异。计算了EMS人员获得理论上NA给药知情同意的能力。
本研究共纳入222例患者;其中,75例被认为符合假设的NA给药条件且有完整的时间数据。平均而言,EMS人员记录的NA理论给药时间为到达ED前12.04±2.07分钟(现场给药时为17.06±1.74分钟[n = 43];途中给药时为6.65±1.14分钟[n = 32])。
院前给予NA有可能显著缩短卒中患者首次干预的时间。